• Endocrine therapy is a type of cancer treatment that slows or halts the growth of hormone-sensitive cancers and is…
The third edition of the VHIOVida Festival, which was held on Saturday October 19, in Cabrils, brought together more than…
On the weekend of 19 and 20 October, the massive solidarity initiative Pink Run Palau and Pink Run Mir was…
The Severo Ochoa Digital Oncology Unit (SOUND) is a transversal unit created at the Vall d’Hebron Institute of Oncology (VHIO)…
Co-authored by investigators of VHIO’s Cancer Genomics Group and Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, results…
Dr. Mate Maus, head of the Aging and Cancer Group at VHIO, has been awarded the XXVIII FERO Grant for…
A new drug originally developed by Leukos Biotech S.L., a spin-off of the Josep Carreras Leukaemia Research Institute, in collaboration…
Recently published in The New England Journal of Medicine, results from the phase 3, multicenter DESTINY-06 clinical trial show that…
From the laboratory to the patient: the ”la Caixa” Foundation promotes 29 biomedicine and health projects The ”la Caixa” Foundation…
The 14th edition of the solidarity initiative, the Paseíco de la Mama, took place on 28 September. A historic initiative…
In her latest On target column published by the ESMO Daily Reporter, VHIO’s Elena Garralda discusses the expanding toolbox for immuno-oncology in advanced…
The phase 3 BEACON CRC trial demonstrated that treatment with the BRAF inhibitor encorafenib plus anti-EGFR monoclonal antibody cetuximab, with…
